Accuitis

Accuitis is a private, preclinical biotech founded in 2015 and based in San Diego, California. The company is advancing a novel therapeutic approach centered on restoring mitochondrial health via SIRT3 activation to address neurodegenerative diseases. Its lead asset, AN-018, has undergone extensive preclinical validation but has not yet entered clinical trials. The company operates as a pre-revenue entity, likely funded by private investment, and faces the significant challenges of translating its platform into clinical success.

Small molecule platform targeting mitochondrial dysfunction via restoration of sirtuin 3 (SIRT3) expression to protect and restore cellular health.

Accuitis competes in the crowded neurodegenerative space against large pharma and biotechs pursuing diverse mechanisms (amyloid, tau, neuroinflammation). Its specific SIRT3 focus is less crowded but unproven. In methamphetamine addiction, the competitive landscape is different, with fewer pharmacological players but challenging clinical development pathways.